Thu, March 1, 2012
Wed, February 29, 2012
Tue, February 28, 2012
[ Tue, Feb 28th 2012 ] - Market Wire
Alere to Acquire eScreen, Inc.
[ Tue, Feb 28th 2012 ] - Market Wire
ICON Acquires PriceSpective
Mon, February 27, 2012
Sat, February 25, 2012
Fri, February 24, 2012
[ Fri, Feb 24th 2012 ] - Market Wire
BrainStorm Featured on CNBC
Thu, February 23, 2012
[ Thu, Feb 23rd 2012 ] - Market Wire
00 am ET
Wed, February 22, 2012
Tue, February 21, 2012
Mon, February 20, 2012
Sat, February 18, 2012
Fri, February 17, 2012

30 p.m. ET to Discuss Financial Results for the Fourth Quarter and Year Ended 2011


//health-fitness.news-articles.net/content/2012/ .. -for-the-fourth-quarter-and-year-ended-2011.html
Published in Health and Fitness on Thursday, February 23rd 2012 at 13:39 GMT by Market Wire   Print publication without navigation


LEXINGTON, Mass.--([ ])--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report audited consolidated financial results for the fourth quarter and year ended December 31, 2011 after the U.S. financial markets close on March 5, 2012. The announcement will be followed by a conference call and webcast with slides at 4:30 p.m. ET during which management will discuss the companyas financial results, commercial progress and development programs.

To access the conference call via telephone, please dial (877) 412-6083 from the United States or (702) 495-1202 for international access. A telephone replay will be available from approximately 8:30 p.m. ET on March 5, 2012 through midnight March 9, 2012. To access a replay of the conference call, dial (855) 859-2056 from the United States or (404) 537-3406 for international access. The pass code for the live call and the replay is 56349072.

The call will be webcast with slides and accessible through the Investors section of the Companyas website at [ www.amagpharma.com ]. The webcast replay will be available from approximately 8:30 p.m. ET on March 5, 2012 through midnight April 5, 2012.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia. AMAG manufactures and sells Feraheme (ferumoxytol) Injection for intravenous use. For additional company or product information, please visit [ www.amagpharma.com ] or [ http://feraheme.com ].

Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.


Publication Contributing Sources